Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Governance at a Glance
| Board Members | Audit | Compensation | Corporate Governance and Nominating | Independent Investment | Succession |
|---|---|---|---|---|---|
|
Audit
|
Compensation
|
Corporate Governance and Nominating
|
Independent Investment
|
||
|
Compensation
|
Corporate Governance and Nominating
|
||||
|
Audit
|
Corporate Governance and Nominating
|
Independent Investment
|
Succession
|
||
|
Audit
|
Succession
|
||||
Committee Charters
Phillip Frost, M.D.
Dr. Frost has been CEO and Chairman of OPKO since March 2007. Previously, he served as Chairman and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He has served as Chairman for Key Pharmaceuticals from 1972 until its acquisition by Schering Plough Corporation in 1986 and Ladenburg Thalmann Financial Services from 1977 until its acquisition by Schering Plough in 1986, and was a Director of Castle Brands and Northrop Grumman. He was also a Governor of the American Stock Exchange from 1992 to 2008 and Co-Vice Chairman from 2001 until its merger with the New York Stock Exchange.
Dr. Frost has been a member of the Board of Trustees of the University of Miami since 1983 and was Chairman from 2001 to 2004 e Trustee of the Miami Jewish Home for the Aged and serves on the Executive Committee of the Mount Sinai Medical Center. He also serves e is a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Regents of The Smithsonian Institution from 2006 to 2010.
Dr. Frost is a Director of Cocrystal Pharma, a publicly traded biotechnology company developing new treatments for viral diseases, and Non-Invasive Monitoring Systems, Inc., a public shell company.
Jane Hsiao, Ph.D.
Dr. Hsiao has served as Vice Chairman and Chief Technical Officer at OPKO since May 2007 and as a Director since February 2007. Previously, Dr. Hsiao served as Vice Chairman-Technical Affairs of IVAXfrom 1995 to Januarry 2006, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary from 1998 to 2006. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical and Neovasc.
Since 2008 Dr. Hsiao has served as Chairman of the Board of Non-Invasive Monitoring Systems, a medical device company, and was named interim CEO of the company in 2012. Dr. Hsiao is also a Director of Asensus Surgical, Inc., a medical device company, and Cocrystal Pharma.
Elias A. Zerhouni, M.D.
Dr. Zerhouni is Chairman and co-founder of ModeX Therapeutics, OPKO’s wholly-owned subsidiary focused on delivering multispecific therapies for cancer and viral diseases, and has served as President and Vice Chairman of OPKO since May 2022. A physician-scientist in Imaging and Biomedical Engineering, he previously served as President of Global R&D and Executive Vice President of Sanofi from 2010 to 2018, as Senior Fellow for global health research at the Bill & Melinda Gates Foundation and as Presidential U.S. envoy for science and technology from 2009 to 2010. Since 2019, he has also served as a director of B-FLEXION Capital, a private, entrepreneurial investment firm and as Chairman of the Board of Boston Pharmaceuticals, a wholly owned subsidiary of B-FLEXION Capital and a clinical stage biopharmaceutical company, since 2024. He was Director of the U.S. National Institutes of Health from 2002 to 2008, Executive Vice Dean and Dean for Research at the Johns Hopkins School of Medicine, as well as Professor of Radiology and Biomedical Engineering and Chair of the Department of Radiological Sciences from 1996 to 2002.
Dr. Zerhouni was elected to the National Academy of Medicine in 2002 and to the National Academy of Engineering in 2013. He was elected to the governing council of the National Academy of Medicine in 2025. He serves on the Board of the Lasker Foundation, the Foundation for the National Institutes of Health and Research!America. He received the 2017 Scripps Executive of the Year Award for the pharmaceutical industry and the French Legion of Honor in 2008. Since 2009, he has been a Director of Danaher Corporation, a publicly traded a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.
Prem A. Lachman, M.D.
Dr. Lachman has been a Director of OPKO since March 2021. He is a healthcare investment manager with more than 35 years of experience in portfolio management, biopharmaceutical investment research and healthcare investment banking. Dr. Lachman founded Maximus Capital in 2001 and currently serves as its general partner. Dr. Lachman previously served as general partner of The Galleon Group from 1998 to 2001 and as Managing Director, Investment Research at Goldman Sachs & Co from 1989 to 1998. Dr. Lachman is a Directors Council board member of the New York Museum of Modern Art, a board member of the New York Metropolitan Opera and a board member of the Department of Surgery at Mount Sinai Medical Center in New York.
Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Yu has been a Director of OPKO since April 2009. She has been a Professor of Pediatrics for the University of California in San Diego since 1994. From 2003 to 2013, she served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Since 2013, she has been a Distinguished Chair Professor at Chang Gung Memorial Hospital at Linkou, and Chang Gung University in Taiwan.
Dr. Yu has also served as a Professor of Pediatrics for the University of California San Diego, where she was the Chief of Pediatric Hematology Oncology. She is an Academician of Academia Sinica, Taiwan. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations. She has been a long-time member of the Children’s Oncology Group in the United States, serving on the Steering Committee of Neuroblastoma. Dr. Yu currently serves as a director of two private entities, Apexcella Biomedical Inc. and UCT Bioscience, Inc. She was honored with the Pediatric Oncology Award by the American Society of Clinical Oncology (ASCO) in 2020 and the Lifetime Achievement Award from Advances in Neuroblastoma Research Association in 2025.
Roger J. Medel, M.D.
Dr. Medel has been a Director of OPKO since December 2020. He is the co-founder of MEDNAX, a national health solutions partner comprised of the nation’s leading providers of physician services, where he has served as a Director, President and Chief Executive Officer. Dr. Medel currently serves as Chairman of the Board of Istios Health Inc., a privately held healthcare technology company focused on infectious disease care, and Chief Executive Officer of RVM Enterprises, Inc., a privately held investment firm specializing in healthcare and technology growth companies. Dr. Medel has served as a member of the Board of Trustees of the Dana Farber Cancer Institute since 2011 and also has served on the Board of Directors of Schweiger Dermatology Group, a privately held, private equity backed, multi-state dermatology practice, since 2014. He currently serves on the Advisory Committee of MBF Healthcare Partners and, from June 2006 to April 2009, served on the Board of Directors of MBF Healthcare Acquisition Corp. He previously and was a member of the Board of Trustees of the University of Miami from 2004 to 2012. Dr. Medel actively participates as a member of several medical and professional organizations and previously served on the Board of Directors of InnovaCare Health, a privately held, private equity backed, healthcare company.
Gary J. Nabel, M.D., Ph.D.
Dr. Nabel is President and CEO of ModeX Therapeutics, and has served as Chief Innovation Officer and a Director of OPKO since May 2022. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi until his retirement in 2020e Dr. Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his Ph.D. in 1980 and his M.D. two years later, followed by a post-doctoral fellowship with David Baltimore at the Whitehead Institute.
In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the National Academy of Medicine in 1998 and is a fellow of the American Association of Physicians, and the American Academy of Arts Sciences. Dr. Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service. He currently serves on the board of Siga Technologies, a publicly traded a commercial stage pharmaceutical company focused on providing solutions for unmet needs in health security, and Candel Therapeutics, Inc. (NASDAQ: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer.
John A. Paganelli
Mr. Paganelli has served as a Director of OPKO since December 2003. Previously, he served as OPKO's interim CEO and Secretary from 2005 through March 2007, Interim Chief Financial Officer from June 29, 2005 through July 1, 2005, and Chairman of OPKO's Board of Directors from December 2003 until March 2007. Mr. Paganelli also served as President and CEO of Transamerica Life Insurance Company of New York from 1992 to 1997.
Mr. Paganelli is the founder and had been a partner in RFG Associates, a financial planning organization from 197 through 2021. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, an investment company, and served as Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization from 1987 to 2000. Mr. Paganelli was also an officer and director-stockholder of Mike Barnard Chevrolet, an automobile dealership. Mr. Paganelli serves as a Director of Western New York Energy, and previously served on the Board of Trustees of Paul Smith's College from 2001 to 2019.
Richard C. Pfenniger, Jr.
Mr. Pfenniger has served as a Director of OPKO since January 2008. Mr. Pfenniger previously served as CEO and President for Continucare Corporation, a provider of primary care physician and practice management services, from 2003 to 2011 and as Chairman of the Board of Directors of Continucare Corporation from 2002 to 2011. Mr. Pfenniger has also served as CEO and Vice Chairman of Whitman Education Group from 1997 to 2003.
Prior to joining Whitman, he served as Chief Operating Officer of IVAX from 1994 to 1997 and as Senior Vice President-Legal Affairs and General Counsel of IVAX from 1989 to 1994. Prior thereto he was engaged in the private practice of law. Mr. Pfenniger currently serves as a Director of Cocrystal Pharmaceuticals, Inc., a clinical stage biotechnology company, Fluent, Inc., a company utilizing proprietary data science to assist global brands in customer acquisition, and GeneDx Holding Corp., a genomics testing company. Mr. Pfenniger previously served as a director of GP Strategies Corporation, a corporate education and training company, Asensus Surgical, Inc., a medical device company, and BioCardia, a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases. He also serves as Vice Chairman of the Board of Trustees and as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.
Steve Rubin
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a Director since February 2007.
Mr. Rubin currently serves as a Director of Entera Bio Ltd, a clinical stage company focused on developing oral peptide and protein replacement therapeutics; Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation; Non-Invasive Monitoring Systems, a public shell company; Cocrystal Pharma, a biotechnology company developing new treatments for viral diseases; and Niagen Bioscience, Inc., a global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research; and Red Violet, a leading analytics and information solutions provider. Mr. Rubin previously served as a director of Neovasc, Inc., a company that developed and marketed medical specialty vascular devices
Mr. Rubin previously served as a Director of Castle Brands, Dreams, SafeStitch Medical, Cogent, PROLOR Biotech, BioCardia and VBI Vaccines.
Subbarao V. Uppaluri, Ph.D.
Dr. Uppaluri has served as a Director of OPKO since March 2026. Previously, Dr. Uppaluri served as Senior Vice President and Chief Financial Officer of the Company from May 2007 until his retirement in July 2012, and as a consultant of the Company until February 2014. He served as Vice President, Strategic Planning and Treasurer of IVAX from 1997 to 2006. Dr. Uppaluri was Senior Vice President, Senior Financial Officer and Chief Investment Officer with Intercontinental Bank, a publicly traded commercial bank in Florida from 1987 to 1996. In addition, he served in various positions, including Senior Vice President, Chief Investment Officer and Controller, at Peninsula Federal Savings & Loan Association, a publicly traded Florida savings and loan institution, from 1983 to 1987. His prior employment, from 1974 to 1983, included engineering, marketing and research positions with multinational companies and research institutes in India and the United States. Dr. Uppaluri previously served on the boards of Non-Invasive Monitoring Systems, Inc. from 2008 until 2025. Winston Pharmaceuticals Inc., Ideation Acquisition Corp., Tiger X Medical, Inc. and Kidville, Inc.. Dr. Uppaluri currently serves on the board of Baptist Health Homestead Hospital.